EARNINGS ROUND-UP: ILMN, SYK, TMO, VAR
This article was originally published in Clinica
Genome sequencing specialist Illumina’s share price jumped after it posted 27% sales growth during its first fiscal quarter. Its stock closed up 5% at $147.98 on 22 April, the day it reported the results, and climbed another 4% to close at $153.69 the following day. Its share price hit an all-time high of $179.65 in February, making a mockery of Roche’s $51 per share offer in 2012. Illumina has increased its guidance for full-year 2014 and is now predicting 21-23% revenue growth (from 15-17% previously) and non-GAAP earnings of $2.10-2.15 per diluted share (from $2.00-2.06).